Helixa Cruises is preparing to launch a next-generation, medical-grade longevity program at sea starting from October 2027, operating on a Dubai to Singapore route.

Designed as a fully integrated clinical environment rather than a traditional cruise, the program combines advanced stem cell and regenerative treatments with precision diagnostics, physician-led protocols and continuous monitoring within a controlled maritime setting. The vessel is being developed to support structured, long-duration health optimisation, where treatments, recovery and follow-up are delivered as part of a unified system. Participation is limited and subject to medical evaluation to ensure suitability and alignment with the program’s longevity objectives.